Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study
Javier Sastre(Hospital Clínico San Carlos), Eduardo Díaz‐Rubio(Hospital Clínico San Carlos), Bartomeu Massutí(Universitat de Miguel Hernández d'Elx), Josep Tabernero(Deaconess Hospital), Albert Abad, Carlos Fernández-Martos(Fundación Instituto Valenciano de Oncología), Encarnación González‐Flores(Hospital Universitario Virgen de las Nieves), Manuel Benavides(Hospital Clínico Universitario Virgen de la Victoria), Enrique Aranda(Instituto Maimónides de Investigación Biomédica de Córdoba), Manuel Gallén(Hospital Del Mar), Fernando Rivera(Marqués de Valdecilla University Hospital), Marta Vidaurreta, Eugenio Marcuello(Hospital de Sant Pau), M.L. Maestro, Auxiliadora Gómez‐España(Hospital Universitario Reina Sofía), Manuel Valladares(American Society of Clinical Oncology), A. Arriví(Hospital Son Llatzer)
Cited by 88
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k